Ef fi cacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
暂无分享,去创建一个
R. Ortmann | P. Berclaz | W. Komocsar | M. Veenhuizen | Chin H Lee | A. Gill | Thomas Dörner | Michael Schiff | J. Kremer | Rmd Open | Tom W. J. Huizinga | B. Combe